STOCK TITAN

Atomico group owns 2.88% of Hinge Health (HNGE) after 13G/A amendment

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Hinge Health, Inc. Schedule 13G/A amendment reports that Atomico Advisors IV, Ltd., together with affiliated Atomico IV entities, beneficially owns 2,300,000 shares of Class A Common Stock, representing 2.88% of the company’s combined capital stock. The filing states the 79,961,966 total shares outstanding as of April 30, 2026 and discloses that portions of the holdings are subject to share collar contracts dated December 8, 2025.

Positive

  • None.

Negative

  • None.

Insights

Atomico group reports a passive 2.88% stake in Hinge Health.

The amendment lists 2,300,000 shares held with shared voting and dispositive power across Atomico Advisors IV, Ltd., Atomico IV, L.P., and Atomico IV (Guernsey), L.P. Holdings include positions subject to a share collar dated December 8, 2025.

Ownership is presented relative to 79,961,966 total shares outstanding as of April 30, 2026. The filing characterizes the stake as passive and below the 5% threshold; further activity would depend on subsequent amendments or filings.

Reported shares beneficially owned 2,300,000 shares Aggregate holdings across Atomico reporting persons
Percent of combined capital stock 2.88% Based on 79,961,966 total shares outstanding as of April 30, 2026
Shares outstanding referenced 79,961,966 shares Total Class A, Class B, and Series E Preferred outstanding as of April 30, 2026
share collar financial
"subject to a share collar contract dated December 8, 2025"
beneficially owned regulatory
"The number of shares beneficially owned consists of (i) 1,876,570 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Schedule 13G/A regulatory
"This Statement on has been filed on behalf of the following persons"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Atomico hold in Hinge Health (HNGE)?

Atomico beneficially owns 2,300,000 shares, representing 2.88% of combined capital stock. The percentage uses a total of 79,961,966 shares outstanding as of April 30, 2026, per the filing's disclosure.

Are Atomico’s Hinge Health shares restricted or subject to agreements?

Yes. Portions of the holdings are subject to share collar contracts dated December 8, 2025. The filing states specific share blocks held by Atomico entities are governed by those collar agreements.

Which Atomico entities filed the Schedule 13G/A for HNGE?

The filing was made on behalf of Atomico Advisors IV, Ltd., Atomico IV, L.P., and Atomico IV (Guernsey), L.P. with addresses listed for the Cayman and Guernsey entities.

Does the filing indicate active control or voting power by Atomico?

The filing reports 0 sole voting power and 2,300,000 shared voting power, indicating shared voting and dispositive authority rather than sole control over these shares.

What date anchors are used for ownership and outstanding share counts?

Ownership percentages are tied to 79,961,966 total shares outstanding as of April 30, 2026, and the Schedule 13G/A amendment is signed on June 8, 2026 by a reporting representative.





433313103

(CUSIP Number)
04/17/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The number of shares beneficially owned consists of (i) 1,876,570 shares of Class A Common Stock held by Atomico IV L.P., which are subject to a share collar contract dated December 8, 2025, and (ii) 423,430 shares of Class A Common Stock held by Atomico IV (Guernsey), L.P., which are subject to a share collar contract dated December 8, 2025. Atomico Advisors IV, Ltd. is the general partner of Atomico IV L.P. and Atomico IV (Guernsey), L.P. Percentage ownership is based on 79,961,966 total shares of Class A Common Stock, Class B Common Stock, and Series E Preferred Stock outstanding as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 7, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: See comments on the cover page by Atomico Advisors IV, Ltd.


SCHEDULE 13G




Comment for Type of Reporting Person: See comments on the cover page by Atomico Advisors IV, Ltd.


SCHEDULE 13G



Atomico Advisors IV, Ltd.
Signature:/s/ Nicole Ramroop
Name/Title:Director
Date:06/08/2026
Atomico IV, L.P.
Signature:/s/ Nicole Ramroop
Name/Title:Director of Atomico Advisors IV, Ltd., its general partner
Date:06/08/2026
Atomico IV (Guernsey), L.P.
Signature:/s/ Nicole Ramroop
Name/Title:Director of Atomico Advisors IV, Ltd., its general partner
Date:06/08/2026
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Person with the SEC on July 30, 2025).